The influence of covalently linked and free polyethylene glycol on the structural and release properties of rhBMP-2 loaded microspheres

Journal of Controlled Release

Volumn 147, Issue 1, 2010, Pages 92-100

  Lochmann, Alexander ^a,b   Nitzsche, Hagen ^a   von Einem, Sabrina ^b   Schwarz, Elisabeth ^b   Mäder, Karsten ^a,b  

^a Translational Centre for Regenerative Medicine   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Block copolymer; BMP 2; Drug distribution; Labelling; Microspheres; PEG PLGA

Indexed keywords

ADVERSE EFFECT; ALKALINE PHOSPHATASE; BENEFICIAL EFFECTS; BIOLOGICAL ACTIVITIES; BMP-2; CHARACTERISATION; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED DELIVERY; CONTROLLED RELEASE; COSOLVENTS; DELIVERY SYSTEMS; DIBLOCK COPOLYMER; DRUG DISTRIBUTION; ENCAPSULATION EFFICIENCY; ENVIRONMENTAL SCANNING ELECTRON MICROSCOPY; GROWTH FACTOR; HETEROTOPIC OSSIFICATION; HIGH DOSE; HIGH YIELD; HUMAN BONE MORPHOGENETIC PROTEIN; IN-VITRO; INNER PHASE; LABELLING; LASER DIFFRACTIONS; LOW DOSE; MICRO-DOMAINS; PEG-PLGA; PLGA MICROSPHERES; POLY(LACTIC-CO-GLYCOLIC ACID); RELEASE PROFILES; RELEASE PROPERTY; RELEASE RATE; RHBMP-2; RHODAMINE B; STRUCTURAL CHANGE; VERSATILE TOOLS;

BIOACTIVITY; BLOCK COPOLYMERS; CONFOCAL MICROSCOPY; COPOLYMERIZATION; COST REDUCTION; CYTOTOXICITY; ENCAPSULATION; MICROSPHERES; PEPTIDES; PHOSPHATASES; POLYETHYLENE OXIDES; POLYETHYLENES; POLYMER BLENDS; SCANNING ELECTRON MICROSCOPY; THERMOPLASTICS;

POLYETHYLENE GLYCOLS;

ALKALINE PHOSPHATASE; MACROGOL; MICROSPHERE; POLYGLACTIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RHODAMINE B;

ANIMAL CELL; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; LASER DIFFRACTION; LASER MICROSCOPY; MOUSE; MYOBLAST; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ALKALINE PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CELL LINE; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; MYOBLASTS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; PROTEIN STABILITY; RECOMBINANT PROTEINS; SOLUBILITY; SPECTROMETRY, FLUORESCENCE; SURFACE PROPERTIES;

EID: 79952294112     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.06.021     Document Type: Article

References (57)

1. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J. Tissue Eng. Regen. Med. 2008, 2(1):1-13.
2. Shahlaie K., Kim K.D. Occipitocervical fusion using recombinant human bone morphogenetic protein-2: adverse effects due to tissue swelling and seroma. Spine 2008, 33(21):2361-2366.
3. Benglis D., Wang M.Y., Levi A.D. A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery. Neurosurgery 2008, 62(5 Suppl 2):ONS423-ONS431.
4. Boakye M., Mummaneni P., Garrett V.M., Rodts G., Haid R. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J. Neurosurg. Spine 2005, 2(5):521-525.
5. Brower R.S., Vickroy N.M. A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L4-L5. Spine 2008, 33(18):E653-E655.
6. Tumialan L.M., Pan J., Rodts G.E., Mummaneni P.V. The safety and efficacy of anterior cervical discectomy and fusion with polyetheretherketone spacer and recombinant human bone morphogenetic protein-2: a review of 200 patients. J. Neurosurg. Spine 2008, 8(6):529-535.
7. Lin Z.Y., Duan Z.X., Guo X.D., Li J.F., Lu H.W., Zheng Q.X., Quan D.P., Yang S.H. Bone induction by biomimetic PLGA-(PEG-ASP)n copolymer loaded with a novel synthetic BMP-2-related peptide in vitro and in vivo. J. Control. Release 2010, 144(2):190-195.
8. Niu X., Feng Q., Wang M., Guo X., Zheng Q. Porous nano-HA/collagen/PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-2. J. Control. Release 2009, 134(2):111-117.
9. Patel Z.S., Yamamoto M., Ueda H., Tabata Y., Mikos A.G. Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2. Acta Biomater. 2008, 4(5):1126-1138.
10. Wang C.K., Ho M.L., Wang G.J., Chang J.K., Chen C.H., Fu Y.C., Fu H.H. Controlled-release of rhBMP-2 carriers in the regeneration of osteonecrotic bone. Biomaterials 2009, 30(25):4178-4186.
11. Lee M., Li W., Siu R.K., Whang J., Zhang X., Soo C., Ting K., Wu B.M. Biomimetic apatite-coated alginate/chitosan microparticles as osteogenic protein carriers. Biomaterials 2009, 30(30):6094-6101.
12. Jha A.K., Yang W., Kirn-Safran C.B., Farach-Carson M.C., Jia X. Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 2009, 30(36):6964-6975.
13. Balmayor E.R., Feichtinger G.A., Azevedo H.S., van Griensven M., Reis R.L. Starch-poly-epsilon-caprolactone microparticles reduce the needed amount of BMP-2. Clin. Orthop. Relat. Res. 2009, 467(12):3138-3148.
14. Chen F., Chen R., Wang X., Sun H., Wu Z. In vitro cellular responses to scaffolds containing two microencapulated growth factors. Biomaterials 2009, 30(28):5215-5224.
15. Woo B.H., Fink B.F., Page R., Schrier J.A., Jo Y.W., Jiang G., DeLuca M., Vasconez H.C., DeLuca P.P. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm. Res. 2001, 18(12):1747-1753.
16. Bergeron E., Marquis M.E., Chretien I., Faucheux N. Differentiation of preosteoblasts using a delivery system with BMPs and bioactive glass microspheres. J. Mater. Sci. Mater. Med. 2007, 18(2):255-263.
17. Schrier J.A., Fink B.F., Rodgers J.B., Vasconez H.C., DeLuca P.P. Effect of a freeze-dried CMC/PLGA microsphere matrix of rhBMP-2 on bone healing. AAPS PharmSciTech 2001, 2(3):E18-E25.
18. Shen H., Hu X., Yang F., Bei J., Wang S. An injectable scaffold: rhBMP-2-loaded poly(lactide-co-glycolide)/hydroxyapatite composite microspheres. Acta Biomater. 2010, 6(2):455-465.
19. Ruhé P.Q., Hedberg E.L., Padron N.T., Spauwen Paul H.M., Jansen J.A., Mikos A.G. rhBMP-2 release from injectable poly(dl-lactic-co-glycolic acid)/calcium-phosphate cement composites. J. Bone Joint Surg. Am. 2003, 85-A(Suppl 3):75-81.
20. Kempen D.H.R., Yaszemski M.J., Heijink A., Hefferan T.E., Creemers L.B., Britson J., Maran A., Classic K.L., Dhert W.J.A., Lu L. Non-invasive monitoring of BMP-2 retention and bone formation in composites for bone tissue engineering using SPECT/CT and scintillation probes. J. Control. Release 2009, 134(3):169-176.
21. Shi S., Cheng X., Wang J., Zhang W., Peng L., Zhang Y. RhBMP-2 microspheres-loaded chitosan/collagen scaffold enhanced osseointegration: an experimental in dog. J. Biomater. Appl. 2009, 23(4):331-346.
22. Isobe M., Yamazaki Y., Oida S.I., Ishihara K., Nakabayashi N., Amagasa T. Bone morphogenetic protein encapsulated with a biodegradable and biocompatible polymer. J. Biomed. Mater. Res. 1996, 32(3):433-438.
23. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J. Tissue Eng. Regen. Med. 2008, 2(2-3):81-96.
24. Mäder K., Bittner B., Li Y., Wohlauf W., Kissel T. Monitoring microviscosity and microacidity of the albumin microenvironment inside degrading microparticles from poly(lactide-co-glycolide) (PLG) or ABA-triblock polymers containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethylene oxide) B blocks. Pharm. Res. 1998, 15(5):787-793.
25. Péan J.M., Boury F., Venier-Julienne M.C., Menei P., Proust J.E., Benoit J.P. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres?. Pharm. Res. 1999, 16(8):1294-1299.
26. Al-Azzam W., Pastrana E.A., King B., Mendez J., Griebenow K. Effect of the covalent modification of horseradish peroxidase with poly(ethylene glycol) on the activity and stability upon encapsulation in polyester microspheres. J. Pharm. Sci. 2005, 94(8):1808-1819.
27. D. Schwartz, Development of an Aqueous Suspension of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2), PhD thesis, LMU Munich, Germany, (2005).
28. Luca L., Capelle M.A.H., Machaidze G., Arvinte T., Jordan O., Gurny R. Physical instability, aggregation and conformational changes of recombinant human bone morphogenetic protein-2 (rhBMP-2). Int. J. Pharm. 2010, 391(1-2):48-54.
29. Augsten C., Kiselev M.A., Gehrke R., Hause G., Mäder K. A detailed analysis of biodegradable nanospheres by different techniques-A combined approach to detect particle sizes and size distributions. J. Pharm. Biomed. Anal. 2008, 47(1):95-102.
30. Hillger F., Herr G., Rudolph R., Schwarz E. Biophysical comparison of BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor. J. Biol. Chem. 2005, 280(15):14974-14980.
31. Lee J.H., Kim C.S., Choi K.H., Jung U.W., Yun J.H., Choi S.H., Cho K.S. The induction of bone formation in rat calvarial defects and subcutaneous tissues by recombinant human BMP-2, produced in Escherichia coli. Biomaterials 2010, 31(13):3512-3519.
32. Witschi C., Doelker E. Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing. J. Control. Release 1998, 51(2,3):327-341.
33. C. Wischke, Protein loaded microparticles with modified surfaces for the targeting of dendritic cells, PhD thesis, FU Berlin, Germany, (2006).
34. Patterson J., Stayton P.S., Li X. In situ characterization of the degradation of PLGA microspheres in hyaluronic acid hydrogels by optical coherence tomography. IEEE Trans. Med. Imaging 2009, 28(1):74-81.
35. Musumeci T., Ventura C.A., Giannone I., Ruozi B., Montenegro L., Pignatello R., Puglisi G. PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm. 2006, 325(1-2):172-179.
36. Berger J., Reist M., Chenite A., Felt-Baeyens O., Mayer J.M., Gurny R. Pseudo-thermosetting chitosan hydrogels for biomedical application. Int. J. Pharm. 2005, 288(2):197-206.
37. Scheufler C., Sebald W., Hülsmeyer M. Crystal structure of human bone morphogenetic protein-2 at 2.7Å resolution. J. Mol. Biol. 1999, 287(1):103-115.
38. ISO 13320:2009 Particle size analysis-laser diffraction methods 2009.
39. A. Rawle, P. Kippax, Setting New Standards for Laser Diffraction Particle Analysis, (2010). http://www.iscpubs.com/Media/PublishingTitles/Rawle-layout-1.pdf.
40. Jeong J.H., Lim D.W., Han D.K., Park T.G. Synthesis, characterization and protein adsorption behaviors of PLGA/PEG di-block co-polymer blend films. Colloids Surf. B Biointerfaces 2000, 18(3,4):371-379.
41. Park J.H., Ye M., Park K. Biodegradable polymers for microencapsulation of drugs. Molecules 2005, 10(1):146-161.
42. Sah H. A new strategy to determine the actual protein content of poly(lactide-co-glycolide) microspheres. J. Pharm. Sci. 1997, 86(11):1315-1318.
43. Kissel T., Li Y., Unger F. ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Adv. Drug Deliv. Rev. 2002, 54(1):99-134.
44. Ding A.G., Schwendeman S.P. Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy. Pharm. Res. 2008, 25(9):2041-2052.
45. Kang F., Singh J. Effect of additives on the release of a model protein from PLGA microspheres. AAPS PharmSciTech 2001, 2(4):30-36.
46. Kempe S., Metz H., Pereira P.G.C., Mäder K. Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy. Eur. J. Pharm. Biopharm. 2010, 74(1):102-108.
47. Sah H. Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. J. Control. Release 1999, 58(2):143-151.
48. D'Souza S.S., DeLuca P.P. Methods to Assess in Vitro Drug Release from Injectable Polymeric Particulate Systems. Pharm. Res. 2006, 23(3):460-474.
49. Witt C., Mäder K., Kissel T. The degradation, swelling and erosion properties of biodegradable implants prepared by extrusion or compression moulding of poly(lactide-co-glycolide) and ABA triblock copolymers. Biomaterials 2000, 21(9):931-938.
50. Varde N.K., Pack D.W. Microspheres for controlled release drug delivery. Expert Opin. Biol. Ther. 2004, 4(1):35-51.
51. Keskin D.S., Tezcaner A., Korkusuz P., Korkusuz F., Hasirci V. Collagen-chondroitin sulfate-based PLLA-SAIB-coated rhBMP-2 delivery system for bone repair. Biomaterials 2005, 26(18):4023-4034.
52. Jeon O., Song S.J., Kang S.W., Putnam A.J., Kim B.S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(-lactic-co-glycolic acid) scaffold. Biomaterials 2007, 28(17):2763-2771.
53. Maeda H., Sano A., Fujioka K. Controlled release of rhBMP-2 from collagen minipellet and the relationship between release profile and ectopic bone formation. Int. J. Pharm. 2004, 275(1-2):109-122.
54. Chen F.M., Zhao Y.M., Sun H.H., Jin T., Wang Q.T., Zhou W., Wu Z.F., Jin Y. Novel glycidyl methacrylated dextran (Dex-GMA)/gelatin hydrogel scaffolds containing microspheres loaded with bone morphogenetic proteins: formulation and characteristics. J. Control. Release 2007, 118(1):65-77.
55. Kempen D.H.R., Lu L., Hefferan T.E., Creemers L.B., Maran A., Classic K.L., Dhert W.J.A., Yaszemski M.J. Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials 2008, 29(22):3245-3252.
56. Ruhé P.Q., Boerman O.C., Russel F.G.M., Spauwen P.H.M., Mikos A.G., Jansen J.A. Controlled release of rhBMP-2 loaded poly(dl-lactic-co-glycolic acid)/calcium phosphate cement composites in vivo. J. Control. Release 2005, 106(1-2):162-171.
57. Bronner F., Farach-Carson M.C., Mikos A.G. Engineering of functional skeletal tissues 2007, Springer, London. first ed.